Streetbeat News

Analyst Ratings

PCRFY

Panasonic Holdings (OTC:PCRFY) reported Q1 earnings of $0.63 per share, beating the analyst consensus estimate of $0.21 by 200%. However, the company's quarterly sales of $14.80 billion missed the analyst consensus estimate of $15.07 billion by 1.82%.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 10:19 am

CHTR

Barclays analyst Kannan Venkateshwar has maintained an Underweight rating on Charter Communications (NASDAQ:CHTR) and raised the price target from $273 to $325.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:16 am

MDNA

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Medicenna Therapeutics (NASDAQ:MDNA) and maintained a price target of $2.5.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:16 am

AQST

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:15 am

CMCSA

Barclays analyst Kannan Venkateshwar has maintained an Equal-Weight rating on Comcast (NASDAQ:CMCSA) and raised the price target from $42 to $47.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:15 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a price target of $51.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:14 am

DXCM

Barclays analyst Matt Miksic maintains an Equal-Weight rating on DexCom (NASDAQ:DXCM) and raises the price target from $115 to $138.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:14 am

BCPC

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Balchem (NASDAQ:BCPC) and raises the price target from $150 to $165.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:13 am

NYXH

HC Wainwright & Co. analyst Edward White has initiated coverage on Nyxoah (NASDAQ:NYXH) with a Buy rating and a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:12 am

FDMT

HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $36 price target.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:11 am